Long-term persistence of anti-HBs after vaccination with a recombinant DNA yeast-derived hepatitis B vaccine: 8-year results

Vaccine

Volumn 16, Issue 20, 1998, Pages 1933-1935

  Van Herck, Koen ^a   Van Damme, Pierre ^a   Thoelen, Stefan ^a   Meheus, André ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Adults; Hepatitis B; Long term persistence of anti HBs; Vaccination

Indexed keywords

DNA VACCINE; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B VACCINE;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CORRELATION FUNCTION; DRUG ACTIVITY; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MALE; NORMAL HUMAN; PRIORITY JOURNAL; QUESTIONNAIRE; RADIOIMMUNOASSAY;

ADULT; FEMALE; FOLLOW-UP STUDIES; HEPATITIS B ANTIBODIES; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION, SECONDARY; MALE; VACCINES, DNA;

EID: 0032391818     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(98)00126-1     Document Type: Article

References (22)

1. 1 Van Damme, P., Eylenbosch, W., Safary, A. and André, F. Immunogenicity of a yeast-derived recombinant DNA vaccine against hepatitis B in medical students. In: Progress in Hepatitis B Immunization, Proceedings of the Symposium 3-5 May 1989 (Eds. Coursaget, P. and Tong, M.J.). Colloque INSERM, John Libbey Eurotext, London, 1990, pp. 273-274.
2. 2 Hollinger, F.B., Adam, E., Heiberg, D. and Melnick, J.L. Response to hepatitis B vaccine in a young adult population. In: Viral Hepatitis and Liver Disease (Eds. Szmuness, W., Alter, H.J. and Maynard, J.M.). Franklin Institute Press, Philadelphia, 1982, pp. 451-465.
3. 3 Anonymous. Immunisation against hepatitis B. Lancet 1988, 8590, 875-876.
4. 4 Centers for Disease Control. Recommendations for protection against viral hepatitis. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR, 1985, 34, 313-335.
5. 5 Gesemann, M. and Scheiermann, N. Quantification of hepatitis B vaccine-induced antibodies as a predictor of anti-HBs persistence. Vaccine 1995, 13, 443-447.
6. 6 Westmoreland, D., Player, V., Heap, D.C. et al. Immunization against hepatitis B - what can we expect? Epid. Infect. 1990, 104, 499-509.
7. 7 Jilg, W., Schmidt, M., Deinhardt, F. et al. Hepatitis B vaccination: how long does protection last? Lancet 1984, 2, 458.
8. 8 Jilg, W., Schmidt, M. and Deinhardt, F. Vaccination against hepatitis B: comparison of three different vaccination schedules. J. Infect. Dis. 1989, 160, 766-769.
9. 9 West, D.J. and Calandra, G.B. Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination. Vaccine 1996, 14, 1019-1027.
10. 10 Van Hattum, J., Maikoe, T., Poel, J. et al. In vitro anti-HBs production by individual B cells of responders to hepatitis B vaccine who subsequently lost antibody. In: Viral Hepatitis and Liver Disease (Eds. Hollinger, F.B., Lemon, S.M. and Margolis, H.S.). Williams and Wilkins, Baltimore, 1991, pp. 774-776.
11. 11 Van Hattum, J., Maikoe, T., Poel, J. et al. Persistence of immune memory in responders to hepatitis B vaccine who subsequently lost serum anti-HBs. Neth. J. Med. 1991, 39, A74.
12. 12 Hadler, S.C., Francis, D.P., Maynard, J.E. et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. NEJM 1986, 315, 209-214.
13. 13 Trivello, R., Chiaramonte, M., Ngatchu, T. et al. Persistence of anti-HBs antibodies in health care personnel vaccinated with plasma derived hepatitis B vaccine and response to recombinant DNA HB booster vaccine. Vaccine 1995, 13, 139-141.
14. 14 Bucher, B., Francioli, P., Geudelin, B. et al. Immunogenicity of a recombinant pre-S2-containing hepatitis B vaccine versus plasma-derived vaccine administered as a booster. Eur. J. Clin. Microbiol. Infect. Dis. 1994, 13, 212-217.
15. 15 Krugman, S. and Davidson, M. Hepatitis B vaccine: prospects for duration of immunity. Yale J. Biol. Med. 1987, 60, 333-338.
16. 16 Milne, A. and Waldon, J.A. Recombinant DNA hepatitis B vaccination in teenagers: effect of a booster at 5 1/2 years. Infect. Dis. 1992, 166, 942.
17. 17 Milne, A., Krugman, S., Waldon, J.A. et al. Hepatitis B vaccination in children: five year booster study. N.Z. Med. J. 1992, 105, 336-338.
18. 18 Wainwright, R.B., McMahon, B.J., Bulkow, L.R. et al. Duration of immunogenicity and efficacy of hepatitis B vaccine in a Yupik Eskimo population. J. Am. Med. Assoc. 1989, 261, 2362-2366.
19. 19 Hadler, S.C., Coleman, P.J., O'Malley, P. et al. Evaluation of long-term protection by hepatitis B vaccine for seven to nine years in homosexual men. In: Viral Hepatitis and Liver Disease (Eds. Hollinger, F.B., Lemon, S.M. and Margolis, H.S.). Williams and Wilkins, Baltimore, 1990, pp. 766-768.
20. 20 Zhang, M., Lie, K., Ding, L. et al. Duration and efficacy of immune response to hepatitis B vaccine in high-risk Chinese adolescents. Clin. Infect. Dis. 1993, 16, 165-167.
21. 21 Lai, C.L., Wong, B.C., Yeah, E.K. et al. Five-year follow-up of a prospective randomised trial of hepatitis B recombinant DNA yeast vaccine vs. plasma-derived vaccine in children: immunogenicity and anamnestic responses. Hepatology 1993, 18, 763-767.
22. 22 Wainwright, R.B., Bulkow, L.R., Parkinson, A.J. et al. Protection provided by hepatitis B vaccine in a Yupik Eskimo population - results of a 10-year study. J. Infect. Dis. 1997, 175, 674-677.